NASDAQ:CMPS Compass Pathways (CMPS) Stock Price, News & Analysis $14.10 -0.68 (-4.60%) As of 12:30 PM Eastern This is a fair market value price provided by Massive. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsFinancialsInsider TradesNews and TrendsOptions ChainOwnershipSEC FilingsShort Interest About Compass Pathways Stock (NASDAQ:CMPS) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get Compass Pathways alerts:Sign Up Key Stats Today's Range$14.01▼$14.7250-Day Range$10.85▼$15.1952-Week Range$4.88▼$15.87Volume967,815 shsAverage Volume3.54 million shsMarket Capitalization$1.95 billionP/E RatioN/ADividend YieldN/APrice Target$23.36Consensus RatingModerate Buy Company Overview Compass Pathways plc (NASDAQ: CMPS) is a biotechnology company developing novel treatments for mental health conditions. The company’s primary focus is psilocybin therapy, which combines a proprietary investigational formulation with psychological support delivered by trained therapists. Its lead candidate, COMP360, is a synthetic crystalline formulation of psilocybin being studied primarily for treatment-resistant depression. Compass Pathways has conducted mid- and late-stage clinical trials evaluating COMP360 and has also investigated its potential use in other difficult-to-treat psychiatric conditions, including post-traumatic stress disorder and anorexia nervosa. These therapies remain investigational and are not approved for general commercial use. Compass Pathways was founded in 2016 and is headquartered in London, with clinical development activities and research collaborations spanning the United States and Europe. The company’s work involves clinical research, therapist training, and the development of systems intended to support the potential delivery of psychedelic-assisted treatments in healthcare settings.AI Generated. May Contain Errors. Read More Compass Pathways Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks49th Percentile Overall ScoreCMPS MarketRank™: Compass Pathways scored higher than 49% of companies evaluated by MarketBeat, and ranked 443rd out of 897 stocks in the healthcare sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion4.4 / 5Analyst RatingModerate Buy Consensus RatingCompass Pathways has received a consensus rating of Moderate Buy. The company's average rating score is 2.88, and is based on 1 strong buy rating, 14 buy ratings, 1 hold rating, and 1 sell rating.Upside PotentialCompass Pathways has a consensus price target of $23.36, representing about 58.0% upside from its current price of $14.78.Amount of Analyst CoverageCompass Pathways has been the subject of 13 research reports in the past 90 days, demonstrating strong analyst interest in this stock.Read more about Compass Pathways' stock forecast and price target. Earnings and Valuation0.0 / 5Proj. Earnings GrowthDecreasing Earnings GrowthEarnings for Compass Pathways are expected to decrease in the coming year, from ($1.26) to ($1.87) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Compass Pathways is -3.20, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Compass Pathways is -3.20, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Read more about Compass Pathways' valuation and earnings. Short Interest1.0 / 5Short Interest LevelBearish Percentage of Shares Shorted10.75% of the float of Compass Pathways has been sold short.Short Interest Ratio / Days to CoverCompass Pathways has a short interest ratio ("days to cover") of 6.48.Change versus previous monthShort interest in Compass Pathways has recently increased by 2.62%, indicating that investor sentiment is decreasing. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldCompass Pathways does not currently pay a dividend.Dividend GrowthCompass Pathways does not have a long track record of dividend growth. News and Social Media2.4 / 5News Sentiment-0.18 News SentimentCompass Pathways has a news sentiment score of -0.18. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.50 average news sentiment score of Healthcare companies.News Coverage This WeekMarketBeat has tracked 6 news articles for Compass Pathways this week, compared to 5 articles on an average week.Search Interest20 people have searched for CMPS on MarketBeat in the last 30 days. This is an increase of 18% compared to the previous 30 days.MarketBeat Follows8 people have added Compass Pathways to their MarketBeat watchlist in the last 30 days. This is an increase of 14% compared to the previous 30 days. Company Ownership0.7 / 5Insider TradingN/A Insider Buying vs. Insider SellingIn the past three months, Compass Pathways insiders have not sold or bought any company stock.Percentage Held by Insiders2.82% of the stock of Compass Pathways is held by insiders.Percentage Held by Institutions46.19% of the stock of Compass Pathways is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Compass Pathways' insider trading history. Receive CMPS Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Compass Pathways and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. CMPS Stock News HeadlinesCOMPASS Pathways plc (CMPS) Presents at Deutsche Bank 2026 Healthcare Summit TranscriptSeptember 17, 2026 | seekingalpha.comCOMPASS Pathways plc (CMPS) Presents at Morgan Stanley 24th Annual Global Healthcare Conference TranscriptSeptember 16, 2026 | seekingalpha.comCODE RED: AI Meltdown Imminent?After correctly predicting the 2008 and 2020 stock market meltdowns, I believe this AI company is about to trigger the next crash. The research firm Bernstein Research said this AI company has the power to crash the global economy for a decade, the CEO just issued a CODE RED in an internal memo warning employees they're dealing with a critical situation, and another company executive even implied they might need a government bailout. The last time I saw something like this was in 2008 when I predicted a stock market meltdown just three weeks before Lehman went under.September 23 at 1:00 AM | Paradigm Press (Ad)COMPASS Pathways (CMPS) Stock May Be Fully Priced On Phase 3 DataSeptember 16, 2026 | finance.yahoo.comCompass Pathways to Participate in TD Cowen 6th Annual Novel Mechanisms in Neuropsychiatry Summit on September 23, 2026September 16, 2026 | businesswire.comCompass Pathways Launches ‘Change the Tune in TRD' in the U.S. to Advance HCP Understanding of Treatment-Resistant Depression at Psych Congress 2026September 15, 2026 | businesswire.comCompass Pathways (NASDAQ:CMPS) Hits New 12-Month High - Here's What HappenedSeptember 12, 2026 | americanbankingnews.comFluence Selected by Compass Pathways to Develop Post-Approval COMP360 Provider TrainingSeptember 10, 2026 | prnewswire.comSee More Headlines CMPS Stock Analysis - Frequently Asked Questions How have CMPS shares performed this year? Compass Pathways' stock was trading at $6.90 at the beginning of the year. Since then, CMPS stock has increased by 114.2% and is now trading at $14.78. How were Compass Pathways' earnings last quarter? Compass Pathways PLC Sponsored ADR (NASDAQ:CMPS) posted its earnings results on Wednesday, August, 5th. The company reported ($1.88) EPS for the quarter, missing analysts' consensus estimates of ($0.39) by $1.49. Read the conference call transcript. When did Compass Pathways IPO? Compass Pathways (CMPS) raised $112 million in an initial public offering on Friday, September 18th 2020. The company issued 7,500,000 shares at a price of $14.00-$16.00 per share. Cowen, Evercore ISI and Berenberg served as the underwriters for the IPO and Canaccord Genuity was co-manager. Who are Compass Pathways' major shareholders? Top institutional shareholders of Compass Pathways include Hennion & Walsh Asset Management Inc. (0.31%), Engineers Gate Manager LP (0.12%), Squarepoint Ops LLC (0.10%) and Stableford Capital II LLC (0.07%). Insiders that own company stock include Life Sciences NV Atai, Ekaterina Malievskaia and George Jay Goldsmith. View institutional ownership trends. How do I buy shares of Compass Pathways? Shares of CMPS stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Compass Pathways own? Based on aggregate information from My MarketBeat watchlists, some other companies that Compass Pathways investors own include Symbotic (SYM), Enovix (ENVX), Rambus (RMBS), JPMorgan Nasdaq Equity Premium Income ETF (JEPQ), Ginkgo Bioworks (DNA), Toast (TOST) and Saia (SAIA). Company Calendar Last Earnings8/05/2026Today9/23/2026TD Cowen 6th Annual Novel Mechanisms in Neuropsychiatry Summit9/23/2026Next Earnings (Estimated)11/03/2026Fiscal Year End12/31/2026Get Stock Alerts Health Indicator TradeSmith's Health IndicatorA long-term volatility-based measure designed for securities held 12 months or longer.Green: Strong and healthy uptrend with normal pullbacks.Yellow: Significant pullback but still within expected volatility.Red: Dropped beyond expected volatility; considered unhealthy. Green Zone (5m+) 1-Year History Sep 25 Dec 25 Mar 26 Jun 26 Sep 26 CMPS's financial health is in the Green zone, according to TradeSmith. CMPS has been in this zone for over 5 months. Industry, Sector and Symbol Stock ExchangeNASDAQ SectorHealthcare Industry Pharmaceuticals Sub-IndustryPharmaceuticals Current SymbolNASDAQ:CMPS CIK1816590 Webwww.compasspathways.com Phone716-676-6461FaxN/AEmployees156Year Founded2016Price Target and Rating Average Price Target for Compass Pathways$23.36 High Price Target$65.00 Low Price Target$13.00 Potential Upside/Downside+66.6%Consensus RatingModerate Buy Rating Score (0-4)2.88 Research Coverage17 Analysts Profitability EPS (Trailing Twelve Months)($4.62) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$287.86 million Net MarginsN/A Pretax MarginN/A Return on Equity-49.63% Return on Assets-13.08% Debt Debt-to-Equity Ratio0.60 Current Ratio1.30 Quick Ratio1.30 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value($0.55) per share Price / Book-25.49Miscellaneous Outstanding Shares138,480,000Free Float134,572,000Market Cap$1.94 billion OptionableOptionable Beta2.54 Social Links Don't Wait for the OpenAI IPOThe AI wave will soon hit public markets with Anthropic and OpenAI set to go public later this year. However, you don't have to wait to invest. This report shows seven AI stocks that you can buy today while the big model providers get ready to go public.Get This Free Report This page (NASDAQ:CMPS) was last updated on 9/23/2026 by MarketBeat.com Staff. From Our PartnersALERT: Drop these 5 stocks before the market opens tomorrow!The Wall Street Journal is already raising the alarm about a potential market crash, and Weiss Ratings researc...Weiss Ratings | SponsoredSmall Colorado Company (Backed by Sam Altman) Could Save U.S. Power GridA small Colorado company has secured rights to technology that could prevent the U.S. public power grid from c...Altimetry | SponsoredLouis Navellier: My #1 AI stock for 2026 (name & ticker inside)Louis Navellier's Stock Grader system helped him flag Nvidia before its 82,000% run and has identified the top...InvestorPlace | SponsoredReady to give options a try? Your first trade (Ticker included) -INSIDETired of trying tactic after tactic when it comes to options trades... only to be met with market noise and st...Base Camp Trading | SponsoredHere’s the stock symbol I’ve promisedWhitney Tilson of Stansberry Research has long recommended Berkshire Hathaway as a core retirement holding - b...Stansberry Research | SponsoredHere’s Why Trump Won’t End The Iran WarTrump has called an Iran deal close 38 times since the war began, yet the fighting keeps flaring back up. O...Banyan Hill Publishing | SponsoredThese gold assets are priced for $1,800 gold [it's over $4,000]Gold's major miners are generating record free cash flow, with margins as high as 75 percent even after gold's...Golden Portfolio | SponsoredYour book is insideThe "Sucker's Bet" Most New Options Traders Fall For Most people who try options lose money the same way. ...Profits Run | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Compass Pathways PLC Sponsored ADR Please log in to your account or sign up in order to add this asset to your watchlist. Share Compass Pathways With A Colleague Link copied to clipboard. Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
